Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Pfizer reported a quarter that beat Wall Street expectations and increased the lower end of its full-year revenue outlook, pointing to continued strength in Eliquis sales.
THE APEX TIMES
THE APEX TIMES
The company boosted its full-year sales guidance by $500 million following stronger-than-expected results in the quarter.
THE APEX TIMES
The companies said they signed a Clinical Trial Collaboration and Supply Agreement to evaluate Amplia’s investigational FAK inhibitor narmafotinib in combination with Eli Lilly’s investigational KRAS G12C therapy olomorasib (marketed as Lumakras in the U.S.), in patients with non-small cell lung cancer.
THE APEX TIMES
Pfizer said second-quarter revenue grew 2.6% year over year to $15.03 billion, a result described by Yahoo Finance as beating Wall Street forecasts. The company also reiterated that it expects full-year revenue to grow, though the specific target was not detailed in the cited post.
THE APEX TIMES
The drugmaker says its Phase 3 trial data support moving toward global regulatory filings for LITFULO, an oral therapy aimed at the autoimmune skin condition vitiligo.
THE APEX TIMES
Rising revenues from oncology and cardiovascular medicines helped offset steep declines in Pfizer’s Covid-19 portfolio, according to a market report on the company’s latest quarter.
THE APEX TIMES
Ahead of Eli Lilly’s scheduled earnings report Wednesday morning, options traders are positioning for a move that could carry the stock back toward recent peak levels seen last month.
THE APEX TIMES
Ahead of its second-quarter results, Pfizer is facing heightened attention on how much revenue could be pressured as expiring patents continue to reshape its pipeline economics.
THE APEX TIMES
Eli Lilly & Co., whose shares have been trading above $1,000 for much of the past few years, is increasingly being viewed by Wall Street as a candidate for a stock split as investor demand remains strong for weight-loss and obesity drug stocks.
